FBN1 and metabolic dysfunction-associated steatotic liver disease: Specifically, two separate studies have indicated that genetic suppression of asprosin in adipose tissue or the liver ameliorates MASLD symptoms in diet-induced obese (DIO) mice by altering lipid metabolism enzymes and reducing inflammation [17,18].